Trial Profile
A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2021
Price :
$35
*
At a glance
- Drugs Opicinumab (Primary)
- Indications Optic neuritis
- Focus Therapeutic Use
- Acronyms RENEWED
- Sponsors Biogen
- 22 Apr 2021 Results A Post Hoc Analysis of RENEW and RENEWED presented at the 73rd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 24 Feb 2017 Status changed from recruiting to completed.